| CEL-SCI Receives Approval to begin Phase III Trial of Multikine in India |
 |
 |
| By Staff and Wire Reports | |
| Wednesday, 20 October 2010 08:55 | |
 CEL-SCI Corporation (AMEX: CVM), the company which is developing products that empower immune defenses, announced today it has received approval from seven hospital Institutional Review Boards (“IRB”) in India to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company’s flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare. CEL-SCI expects to have fifteen clinical centers in India, out of an expected forty-eight clinical centers world-wide. Head and neck cancer is the most prevalent form of cancer in India with about 200,000 new patients annually.
Last year, the company financed and finished building a $25 million state-of-the-art manufacturing facility which will produce the highly specialized drug. CEL-SCI’s Phase III clinical trial is an open-label, randomized, multi-center study. North Mississippi Health Services was the first site in the United States to approve enrollment of subjects. Investors are monitoring the developments closely as Phase II clinical trials of Multikine demonstrated the product was safe and well-tolerated and eliminated tumors in 12% of the subjects less than a month into treatment. The Multikine treatment regimen was also shown to kill, on average, about half of the cancer cells in the subjects’ tumors before the start of standard therapy. "Featured Content" profiles are meant to provide awareness of these companies to investors in the small-cap and growth equity community and should not in any way come across as a recommendation to buy, sell or hold these securities. BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'. Add this page to your favorite Social Bookmarking websites            |
Newsletter
